| 1 | A Systematic Review of Conversion to Resectability in Unresectable Metastatic Colorectal Cancer Chemotherapy Trials. (Chrabaszcz S, Rajeev R, Witmer HDD, Dhiman A, Klooster B, Gamblin TC, Banerjee A, Johnston FM, Turaga KK) Am J Clin Oncol 2022 Aug 01;45(8):366-372 2 Citations |
| 1 | Another Signal from DEBIRI. (Soulen MC, White SB) Ann Surg Oncol 2022 Sep;29(9):5357-5358 |
| 1 | Expression of GM-CSF Is Regulated by Fli-1 Transcription Factor, a Potential Drug Target. (Wang X, Lennard Richard M, Li P, Henry B, Schutt S, Yu XZ, Fan H, Zhang W, Gilkeson G, Zhang XK) J Immunol 2021 Jan 01;206(1):59-66 12 Citations |
| 3 | Nitric Oxide Suppresses β-Cell Apoptosis by Inhibiting the DNA Damage Response. (Oleson BJ, Broniowska KA, Naatz A, Hogg N, Tarakanova VL, Corbett JA) Mol Cell Biol 2016 Aug 01;36(15):2067-77 37 Citations |
| 1 | Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. (Martin RC 2nd, Scoggins CR, Schreeder M, Rilling WS, Laing CJ, Tatum CM, Kelly LR, Garcia-Monaco RD, Sharma VR, Crocenzi TS, Strasberg SM) Cancer 2015 Oct 15;121(20):3649-58 123 Citations |
| 1 | Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. (Said R, Kurzrock R, Naing A, Hong DS, Fu S, Piha-Paul SA, Wheler JJ, Janku F, Kee BK, Bidyasar S, Lim J, Wallace M, Tsimberidou AM) Invest New Drugs 2015 Aug;33(4):911-20 7 Citations |
| 1 | Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. (Schmainda KM, Zhang Z, Prah M, Snyder BS, Gilbert MR, Sorensen AG, Barboriak DP, Boxerman JL) Neuro Oncol 2015 Aug;17(8):1148-56 105 Citations |
| 2 | Neoadjuvant therapy for localized pancreatic cancer: support is growing? (Evans DB, Ritch PS, Erickson BA) Ann Surg 2015 Jan;261(1):18-20 19 Citations |
| 2 | Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. (Wong SJ, Moughan J, Meropol NJ, Anne PR, Kachnic LA, Rashid A, Watson JC, Mitchell EP, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG) Int J Radiat Oncol Biol Phys 2015 Jan 01;91(1):116-23 31 Citations |
| 1 | Old drug new use--amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity. (Kong R, Liu T, Zhu X, Ahmad S, Williams AL, Phan AT, Zhao H, Scott JE, Yeh LA, Wong ST) Clin Cancer Res 2014 Jul 01;20(13):3521-30 78 Citations |
| 2 | Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data. (Santana-Davila R, Szabo A, Arce-Lara C, Williams CD, Kelley MJ, Whittle J) J Thorac Oncol 2014 May;9(5):702-9 44 Citations |
| 1 | Transarterial treatment of colorectal cancer liver metastases with irinotecan-loaded drug-eluting beads: technical recommendations. (Lencioni R, Aliberti C, de Baere T, Garcia-Monaco R, Narayanan G, O'Grady E, Rilling WS, Walker D, Martin RC) J Vasc Interv Radiol 2014 Mar;25(3):365-9 52 Citations |
| 6 | Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? (Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB, George B) Oncologist 2014 Mar;19(3):266-74 171 Citations |
| 1 | Irinotecan-induced immune thrombocytopenia. (Mirtsching BC, George JN, Aster RH, Curtis BR) Am J Med Sci 2014 Feb;347(2):167-9 6 Citations |
| 1 | Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. (Kurzrock R, Goel S, Wheler J, Hong D, Fu S, Rezai K, Morgan-Linnell SK, Urien S, Mani S, Chaudhary I, Ghalib MH, Buchbinder A, Lokiec F, Mulcahy M) Cancer 2012 Dec 15;118(24):6144-51 43 Citations |
| 2 | Evaluation of combined bevacizumab plus irinotecan therapy in brain tumors using magnetic resonance imaging measures of relative cerebral blood volume. (Pechman KR, Donohoe DL, Bedekar DP, Kurpad SN, Schmainda KM) Magn Reson Med 2012 Oct;68(4):1266-72 6 Citations |
| 2 | Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. (Wong SJ, Winter K, Meropol NJ, Anne PR, Kachnic L, Rashid A, Watson JC, Mitchell E, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG) Int J Radiat Oncol Biol Phys 2012 Mar 15;82(4):1367-75 66 Citations |
| 1 | A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. (Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, Tan BR, Pluard TJ, Adkins DR, Naughton MJ, Rader JS, Arquette MA, Fleshman JW, Creekmore AN, Goodner SA, Wright LP, Guo Z, Ryan CE, Tao Y, Soares EM, Cai SR, Lin L, Dancey J, Rudek MA, McLeod HL, Piwnica-Worms H) Cancer Chemother Pharmacol 2011 Jun;67(6):1225-37 57 Citations |
| 1 | The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors. (Choi BS, Alberti DB, Schelman WR, Kolesar JM, Thomas JP, Marnocha R, Eickhoff JC, Ivy SP, Wilding G, Holen KD) Cancer Chemother Pharmacol 2010 Oct;66(5):973-80 18 Citations |
| 1 | Novel dual-reporter preclinical screen for antiastrocytoma agents identifies cytostatic and cytotoxic compounds. (Hawes JJ, Nerva JD, Reilly KM) J Biomol Screen 2008 Sep;13(8):795-803 10 Citations |
| 2 | Synergistic function of E2F7 and E2F8 is essential for cell survival and embryonic development. (Li J, Ran C, Li E, Gordon F, Comstock G, Siddiqui H, Cleghorn W, Chen HZ, Kornacker K, Liu CG, Pandit SK, Khanizadeh M, Weinstein M, Leone G, de Bruin A) Dev Cell 2008 Jan;14(1):62-75 179 Citations |
| 1 | Corneal activation of prothrombin to form thrombin, independent of vascular injury. (Ayala A, Warejcka DJ, Olague-Marchan M, Twining SS) Invest Ophthalmol Vis Sci 2007 Jan;48(1):134-43 14 Citations |
| 1 | Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. (Strock CJ, Park JI, Rosen DM, Ruggeri B, Denmeade SR, Ball DW, Nelkin BD) J Clin Endocrinol Metab 2006 Jan;91(1):79-84 44 Citations |
| 1 | Rectal cancer clinical practice guidelines in oncology. (Engstrom PF, Benson AB 3rd, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW Jr, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ, National Comprehensive Cancer Network) J Natl Compr Canc Netw 2005 Jul;3(4):492-508 21 Citations |
| 1 | Apoptotic pathways of epothilone BMS 310705. (Uyar D, Takigawa N, Mekhail T, Grabowski D, Markman M, Lee F, Canetta R, Peck R, Bukowski R, Ganapathi R) Gynecol Oncol 2003 Oct;91(1):173-8 21 Citations |
| 1 | Novel therapeutic approaches in the treatment of children with hepatoblastoma. (Katzenstein HM, Rigsby C, Shaw PH, Mitchell TL, Haut PR, Kletzel M) J Pediatr Hematol Oncol 2002 Dec;24(9):751-5 36 Citations |
| 1 | Phase I study of rubitecan and gemcitabine in patients with advanced malignancies. (Fracasso PM, Rader JS, Govindan R, Herzog TJ, Arquette MA, Denes A, Mutch DG, Picus J, Tan BR, Fears CL, Goodner SA, Sun SL) Ann Oncol 2002 Nov;13(11):1819-25 8 Citations |
| 1 | Topotecan in platinum- and paclitaxel-resistant ovarian cancer. (Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ) Gynecol Oncol 1997 Sep;66(3):480-6 146 Citations |
